BACKGROUND: Preeclampsia and gestational hypertension are hypothesized to be associated with reduced maternal breast cancer risk, but the epidemiologic evidence is inconclusive. Our objective was to examine associations between gestational hypertensive disorders and breast cancer in a nationwide cohort of women with a family history of breast cancer. METHODS: Women ages 35-74 years who had a sister previously diagnosed with breast cancer, but had never had breast cancer themselves, were enrolled in the Sister Study from 2003 to 2009 (N = 50,884). At enrollment, participants reported diagnoses of eclampsia, preeclampsia, or gestational hypertension in each pregnancy. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between history of a gestational hypertensive disorder and incident invasive breast cancer or ductal carcinoma in situ among 40,720 parous women. We used age as the time scale and adjusted for birth cohort, race-ethnicity, and reproductive, socioeconomic, and behavioral factors. We examined effect measure modification by risk factors for gestational hypertensive disease and breast cancer and assessed possible etiologic heterogeneity across tumor characteristics. RESULTS: The prevalence of gestational hypertensive disease was 12%. During follow-up (mean = 10.9 years), 3,198 eligible women self-reported a breast cancer diagnosis. History of a gestational hypertensive disorder was not associated with breast cancer risk (HR = 1.0; 95% CI = 0.90, 1.1). We did not observe clear evidence of effect measure modification or etiologic heterogeneity. CONCLUSIONS: History of a gestational hypertensive disorder was not associated with breast cancer risk in a cohort of women with a first-degree family history of breast cancer.
BACKGROUND: Preeclampsia and gestational hypertension are hypothesized to be associated with reduced maternal breast cancer risk, but the epidemiologic evidence is inconclusive. Our objective was to examine associations between gestational hypertensive disorders and breast cancer in a nationwide cohort of women with a family history of breast cancer. METHODS: Women ages 35-74 years who had a sister previously diagnosed with breast cancer, but had never had breast cancer themselves, were enrolled in the Sister Study from 2003 to 2009 (N = 50,884). At enrollment, participants reported diagnoses of eclampsia, preeclampsia, or gestational hypertension in each pregnancy. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between history of a gestational hypertensive disorder and incident invasive breast cancer or ductal carcinoma in situ among 40,720 parous women. We used age as the time scale and adjusted for birth cohort, race-ethnicity, and reproductive, socioeconomic, and behavioral factors. We examined effect measure modification by risk factors for gestational hypertensive disease and breast cancer and assessed possible etiologic heterogeneity across tumor characteristics. RESULTS: The prevalence of gestational hypertensive disease was 12%. During follow-up (mean = 10.9 years), 3,198 eligible women self-reported a breast cancer diagnosis. History of a gestational hypertensive disorder was not associated with breast cancer risk (HR = 1.0; 95% CI = 0.90, 1.1). We did not observe clear evidence of effect measure modification or etiologic heterogeneity. CONCLUSIONS: History of a gestational hypertensive disorder was not associated with breast cancer risk in a cohort of women with a first-degree family history of breast cancer.
Authors: Mary Beth Terry; Mary Perrin; Carolyn M Salafia; Fang Fang Zhang; Alfred I Neugut; Susan L Teitelbaum; Julie Britton; Marilie D Gammon Journal: Am J Epidemiol Date: 2007-02-06 Impact factor: 4.897
Authors: Patricia C F M Bezerra; Marcos D Leão; José W Queiroz; Edailna M D Melo; Flávio V M Pereira; Maria Hebe Nóbrega; Ana K Jeronimo; Leonardo C Ferreira; Selma M B Jerônimo; Ana Cristina P F de Araújo Journal: Acta Obstet Gynecol Scand Date: 2010-05 Impact factor: 3.636
Authors: Jung Sun Kim; Eun Joo Kang; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae-Ree Kim; Jae-Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo Journal: Acta Oncol Date: 2012-12-16 Impact factor: 4.089
Authors: Lauren B Wright; Minouk J Schoemaker; Michael E Jones; Alan Ashworth; Anthony J Swerdlow Journal: Int J Cancer Date: 2018-03-23 Impact factor: 7.396
Authors: Zahra Pasdar; David T Gamble; Phyo K Myint; Robert N Luben; Nicholas J Wareham; Kay-Tee Khaw; Sohinee Bhattacharya Journal: Cancers (Basel) Date: 2020-10-23 Impact factor: 6.639